Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Augmentation strategies: focus on anxiolytics

R T Joffe1, A J Levitt, S T Sokolov

  • 1Regional Mood Disorders Program, Hamilton Psychiatric Hospital, Ontario, Canada.

The Journal of Clinical Psychiatry
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Neuroscience and biobehavioral reviews·2018
Same author

Impact of chronically street homeless tenants in congregate supportive housing.

The American journal of orthopsychiatry·2012
Same author

The pharmacological management of depression.

Canadian family physician Medecin de famille canadien·2011
Same author

One-year outcome with antidepressant--treatment of bipolar depression.

Acta psychiatrica Scandinavica·2005
Same author

Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial.

The Journal of clinical endocrinology and metabolism·2003
Same author

Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant.

Acta psychiatrica Scandinavica·2002
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Many patients do not respond fully to initial antidepressant treatment for major depressive episodes. Augmentation strategies, including anxiolytics, show promise for treatment-refractory depression.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Major depressive disorder (MDD) affects a significant portion of the population.
  • A substantial number of patients (20-40%) exhibit inadequate response to first-line antidepressant monotherapy.
  • An additional 20-30% experience only partial symptom improvement.

Purpose of the Study:

  • To review treatment options for patients with suboptimal response to initial antidepressant therapy.
  • To discuss the clinical applications and empirical data supporting various treatment strategies.
  • To specifically examine the role of augmentation agents, including anxiolytics, in managing treatment-refractory depression.

Main Methods:

  • Literature review of studies on antidepressant treatment strategies for major depressive episodes.
  • Analysis of data supporting optimization, substitution, augmentation, and combination therapies.

Related Experiment Videos

  • Focused review on the efficacy and application of anxiolytics as augmentation agents.

    • Main Results:

    • Limited empirical data exist for several treatment options in major depressive disorder.
    • Augmentation strategies demonstrate potential advantages over substitution therapy.
    • Anxiolytics are highlighted as a potential augmentation agent for treatment-resistant depression.

    Conclusions:

    • Treatment optimization, substitution, augmentation, and combination therapy are key options for non-responders.
    • Augmentation strategies, particularly with anxiolytics, warrant further investigation for treatment-refractory depression.
    • Clinical application of these strategies requires careful consideration of available evidence.